In our present study, the heavily-pretreated HER2/neu-negative breast cancer patients achieving objective responses had a 4.2-month median PFS gain (P = 0.000) and 5.7-month median OS gain (P = 0.005) when compared with those who did not achieve objective responses. The gene discussed is ERBB2; the disease is breast cancer.